<DOC>
	<DOC>NCT02435992</DOC>
	<brief_summary>The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).</brief_summary>
	<brief_title>Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis</brief_title>
	<detailed_description>The trial is composed of 2 periods: Induction and Maintenance. Patients will be entered into the trial in 2 separate cohorts through the Induction Period (10 weeks) and those patients in clinical response at the end of the Induction Period will proceed through to the Maintenance Period. Participation in these periods will be 52 weeks. Patients may also qualify to participate in an optional Open-Label Extension study.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Key Ulcerative Colitis (UC) confirmed on endoscopy Moderately to severely active UC (Mayo score 612) Currently receiving treatment with aminosalisylate, prednisone, or budesonide Key Diagnosis of Crohn's disease or indeterminate colitis or the presence or history of a fistula consistent with Crohn's disease or microscopic colitis or radiation colitis or ischemic colitis Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk History of uveitis macular edema Pregnancy, lactation, or a positive serum βhuman chorionic gonadotropin (βhCG) measured during Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>